Saudi Arabia Peptide Supplements Market Size & Outlook, 2025-2033
Saudi Arabia Peptide Supplements Market Insights
- Deep Market Insights analysis indicates that the Saudi Arabia Peptide Supplements Market size, valued at USD 58.27 Million in 2024, is expected to expand to USD 90.83 Million by 2033.
- The Saudi Arabia market is forecasted to expand at a CAGR of 5.1% spanning 2026–2033.
- Collagen held the leading position among Product segments in 2024, based on market size.
- Muscle peptides is projected to post the fastest growth rate, sustaining its position as the most attractive Product segment during the forecast horizon.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, Saudi Arabia held 2.07% of the global Peptide Supplements Market size.
- By 2033, United States is anticipated to capture the largest share of the global Peptide Supplements Market.
- In Middle East and Africa, United Arab Emirates is expected to lead the regional Peptide Supplements Market size by 2033.
- Egypt will remain the fastest-growing market in Middle East and Africa, reaching USD 43.04 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 58.27 Million |
| Market Size In 2033 | USD 90.83 Million |
| Largest segment | Collagen |
| Units | Revenue in USD Million |
| CAGR | 5.1% (2025-2033) |
| Segmnetation Covered | |
| Product |
|
| Application |
|
| Form |
|
| Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Saudi Arabia Peptide Supplements Market Product 2025-2033 (USD Million)
| Product | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collagen | XX.x | XX.x | XX.x | 26.31 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bioactive | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Muscle peptides | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Saudi Arabia Peptide Supplements Market Application 2025-2033 (USD Million)
| Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sports | XX.x | XX.x | XX.x | 28.77 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Anti-aging | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Immunity | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Saudi Arabia Peptide Supplements Market Form 2025-2033 (USD Million)
| Form | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Powder | XX.x | XX.x | XX.x | 31.78 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capsule | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Liquid | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
Saudi Arabia Peptide Supplements Market Channel 2025-2033 (USD Million)
| Channel | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E-commerce | XX.x | XX.x | XX.x | 30.81 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty stores | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.